Advertisement
Research Article Free access | 10.1172/JCI118135
Unité de Pathogénie Microbienne Moléculaire, Unité 389 Institut National de la Santé et de la Recherche Médicale, Paris, France.
Find articles by Sansonetti, P. in: JCI | PubMed | Google Scholar
Unité de Pathogénie Microbienne Moléculaire, Unité 389 Institut National de la Santé et de la Recherche Médicale, Paris, France.
Find articles by Arondel, J. in: JCI | PubMed | Google Scholar
Unité de Pathogénie Microbienne Moléculaire, Unité 389 Institut National de la Santé et de la Recherche Médicale, Paris, France.
Find articles by Cavaillon, J. in: JCI | PubMed | Google Scholar
Unité de Pathogénie Microbienne Moléculaire, Unité 389 Institut National de la Santé et de la Recherche Médicale, Paris, France.
Find articles by Huerre, M. in: JCI | PubMed | Google Scholar
Published August 1, 1995 - More info
The effect of human recombinant interleukin-1 receptor antagonist on intestinal inflammation, tissue destruction, and bacterial invasion during experimental shigellosis caused by Shigella flexneri was studied in the rabbit-ligated loop infection model. Intravenous infusion of the inhibitor at a dose of 2 mg/kg per h, was initiated 30 min before intestinal loops were ligated and infected, and continued during the 8-h period of infection. The animals treated with IL-1 receptor antagonist showed a striking decrease in inflammation, destruction, and bacterial invasion of their tissues, both at the level of the villous intestine and Peyer's patches. This is conclusive evidence that interleukin-1 plays a critical role in the pathogenesis of shigellosis. This proinflammatory cytokine is here proposed as a major trigger of the inflammatory reaction which is characteristic of this invasive disease of the intestine, due to the particular interaction existing between S. flexneri and macrophages.
Images.